Viewpoints on NK cells

Tumor cell recognition by the NK cell activating receptor NKG2D

  1. Yenan T. Bryceson*,
  2. Hans-Gustaf Ljunggren*

Article first published online: 31 OCT 2008

DOI: 10.1002/eji.200838833

Issue

European Journal of Immunology

European Journal of Immunology

Volume 38, Issue 11, pages 2957–2961, November 2008

Additional Information

How to Cite

Bryceson, Y. T. and Ljunggren, H.-G. (2008), Tumor cell recognition by the NK cell activating receptor NKG2D. Eur. J. Immunol., 38: 2957–2961. doi: 10.1002/eji.200838833

Author Information

  1. Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

*Department of Medicine, Karolinska Institutet, Center for Infectious Medicine, 141 86 Stockholm, Sweden Fax: +46-8-746-7637

Publication History

  1. Issue published online: 7 NOV 2008
  2. Article first published online: 31 OCT 2008
  3. Manuscript Accepted: 28 AUG 2008
  4. Manuscript Received: 18 AUG 2008

Funded by

  • Swedish Foundation for Strategic Research
  • Research Council
  • Cancer Society

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (133K)

Keywords:

  • Co-activation;
  • Immune escape;
  • Immunotherapy;
  • NK cells;
  • NKG2D

Abstract

Evidence for increased tumor incidence in NKG2D-deficient mice has set NKG2D as the first innate immune receptor implicated in immunosurveillance of tumors. In this viewpoint article, we discuss recent genetic insight into NKG2D-mediated suppression of spontaneous tumor development in the context of NKG2D signaling properties. Moreover, we identify unresolved issues and consider how an understanding of NKG2D-receptor and -ligand biology can facilitate successful therapeutic intervention of human cancer.

View Full Article (HTML) Get PDF (133K)